Piper Jaffray Remains Sidelined on Teva Pharma (TEVA) Following 1Q - PT to $58
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Qualcomm to issue warrant to Amazon for up to 25M shares
- Trump says Canada's Bombardier must build jets in US or lose market access
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Adamis Pharmaceuticals Announces License Agreement with Allergan plc Subsidiary for Epinephrine Pre-Filled Syringe
May 10, 2016 6:45 AM EDTDUBLIN, Ireland and SAN DIEGO, May 10, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (Adamis) has entered into an exclusive licensing agreement with Allergan plcs wholly owned subsidiary, Watson Laboratories, Inc. (Watson), to commercialize Adamis Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis.
Under the terms of the agreement, Watson will obtain commercial rights for the U.S. in exchange for an upfront fee and potential regulatory and performance based milestone payments totaling up to $32.5 million. Additionally, Watson will pay double-digit royalties to Adamis based on... More
Teva to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
May 9, 2016 11:00 AM EDTJERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Bank of America Merrill Lynch 2016 Health Care Conference. Siggi Olafsson will present on Tuesday, May 10, 2016 at 8:40 AM PT.
ÂWhat:
   Teva Presentation at the Bank of America Merrill Lynch Healthcare Conference ÂWho:
Siggi Olafsson, President and CEO, Global Generic Medicines,Â
Teva Pharmaceutical Industries Ltd.
 ... MoreTeva Reports First Quarter 2016 Results
May 9, 2016 7:00 AM EDTJERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended March 31, 2016.
   Q1 2016  Revenues $4.81 billion Cash flow from Operations $1.38 billion Non-GAAP EPS $1.20 GAAP EPS $0.62... More